Auricular Point Acupressure to Manage Chemotherapy Induced Neuropathy

耳穴按摩治疗化疗引起的神经病变

基本信息

批准号：
10204981
负责人：
Chao Hsing Yeh
金额：
$ 66.94万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-01 至 2021-10-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10204981
关键词：
Acupressure Acupuncture Therapy Adherence Affect Aftercare American Analgesics Anti-Inflammatory Agents Basal Ganglia Biological Markers Bortezomib Brain Cancer Patient Cancer Survivor Cells Characteristics China Clinical Clinical Trials Data Demographic Factors Dose Ear Ear Acupuncture Ecological momentary assessment Equilibrium Esthesia Ethnic Origin Europe Exercise Fatigue Fingers Functional Magnetic Resonance Imaging Functional disorder Gender Goals Hand Health Care Costs Image Inflammatory Interferon Type II Interleukin-1 beta Interleukin-2 Interleukin-6 Intervention Late Effects Malignant Neoplasms Measures Mediating Monitor Needles Neurons Numbness Opioid Pain Pain Threshold Pain management Participant Patient Self-Report Patients Peripheral Nervous System Pharmaceutical Preparations Physical Function Placebo Effect Placebos Plasma Platinum Provider Psychophysics Quality of life Race Randomized Regulation Reporting Resources Seeds Sensory Sensory Thresholds Severities Signal Transduction Sleep Societies Specificity Stimulus Survival Rate Symptoms TNF gene Taiwan Testing Time Toes Vinca Alkaloids active method afferent nerve cancer therapy chemotherapy chemotherapy induced neuropathy cognitive control control trial cytokine design duloxetine effective therapy executive function expectation experience fall risk foot functional disability improved indexing innovation macrophage morphine equivalent neuroimaging opioid use pain relief persistent symptom primary endpoint primary outcome secondary outcome sex side effect smartphone Application taxane tool treatment as usual

Acupressure Acupuncture Therapy Adherence Affect Aftercare American Analgesics Anti-Inflammatory Agents Basal Ganglia Biological Markers Bortezomib Brain Cancer Patient Cancer Survivor Cells Characteristics China Clinical Clinical Trials Data Demographic Factors Dose Ear Ear Acupuncture Ecological momentary assessment Equilibrium Esthesia Ethnic Origin Europe Exercise Fatigue Fingers Functional Magnetic Resonance Imaging Functional disorder Gender Goals Hand Health Care Costs Image Inflammatory Interferon Type II Interleukin-1 beta Interleukin-2 Interleukin-6 Intervention Late Effects Malignant Neoplasms Measures Mediating Monitor Needles Neurons Numbness Opioid Pain Pain Threshold Pain management Participant Patient Self-Report Patients Peripheral Nervous System Pharmaceutical Preparations Physical Function Placebo Effect Placebos Plasma Platinum Provider Psychophysics Quality of life Race Randomized Regulation Reporting Resources Seeds Sensory Sensory Thresholds Severities Signal Transduction Sleep Societies Specificity Stimulus Survival Rate Symptoms TNF gene Taiwan Testing Time Toes Vinca Alkaloids active method afferent nerve cancer therapy chemotherapy chemotherapy induced neuropathy cognitive control control trial cytokine design duloxetine effective therapy executive function expectation experience fall risk foot functional disability improved indexing innovation macrophage morphine equivalent neuroimaging opioid use pain relief persistent symptom primary endpoint primary outcome secondary outcome sex side effect smartphone Application taxane tool treatment as usual

展开

项目摘要

More than 60% cancer patients experience chemotherapy-induced neuropathy (CIN), a severe side effect of chemotherapy (including platinum drugs, vinca alkaloids, taxanes and/or bortezomib). CIN may cause treatment delays, dose reductions, or discontinuation of therapy which can affect survival rates. With improved cancer treatments and longer survival, the late effects of CIN continue to produce a significant burden in up to 50% of cancer survivors who are suffering from CIN 6 years after treatment, with a 1.8-fold increased risk of falls. CIN continues to cause significant functional disability, negatively impacts quality of life, and significantly demands high health care costs and resource use. We propose to test auricular point acupressure (APA)—a non-invasive and nonpharmacological patient managed strategy—as an innovative solution for CIN. APA is developed from auricular acupuncture, which is an invasive (using needles) and passive treatment (administered by a licensed practitioner). APA is a non-invasive and active treatment for patients with pain. It involves needleless acupuncture-like stimulation of ear points. Small seeds are taped on specific ear points by a skilled provider and patients press on the seeds to stimulate ear points three times daily, three minutes per time, for a total of nine minutes per day to achieve pain relief. APA provides pain relief within 1–2 minutes after ear stimulation and sustains pain relief for one month after a 4-week APA intervention. APA is popular in Taiwan, China, and Europe. Though its use is sparse in the U.S., a limited number of clinical trials have supported APA in pain management. This study will provide vital information to gain a comprehensive understanding of underlying mechanism of APA on CIN and provide strong impetus for including APA as part of CIN management in clinical settings.

超过60％的癌症患者经历了化学疗法引起的神经病（CIN），这是一个严重的副作用化学疗法（包括铂药，Vinca生物碱，紫杉烷和/或硼替佐米）。 CIN可能会导致治疗延迟，减少剂量或终止治疗可能会影响存活率。和改善癌症治疗和更长的生存期，CIN的后期影响继续产生重要的在治疗后6年患有CIN的癌症存活中，多达50％的负担为1.8倍跌倒的风险增加。 CIN继续引起严重的功能残疾，对生活，并需要大量的医疗保健成本和资源使用。我们建议测试无侵蚀性和非药物患者托管策略 - 作为CIN的创新解决方案。 APA是由耳针针灸开发的，该针灸是是一种侵入性（使用针）和被动治疗（由执照从业者管理）。 APA是一个疼痛患者的无创和主动治疗。它涉及无针针状刺激耳点。小种子被熟练的提供者在特定的耳朵点上逐渐变细，患者按下种子每天三次刺激早期点，每次三分钟，每天总共九分钟 APA在耳朵刺激后1-2分钟内减轻疼痛，自杀疼痛缓解 4周APA干预后一个月。 APA在台湾，中国和欧洲很受欢迎。虽然它是在美国，使用稀疏，有限数量的临床试验支持APA在疼痛管理方面。这项研究将提供重要信息，以获得对基本机制的全面理解 CIN上的APA，并在临床环境中将APA作为CIN管理的一部分提供了强大的动力。